Ohad Hammer

'When There's Blood in the Streets', Buy Biotech Stocks

beta delta
I am familiar with the company, but not intimately enough for having an opinion. The idea behind TNFerade is very exciting and has broad applications and the data seems pretty good in pancreatic and H&N cancers. Neverthless, I would be very hesitant in investing in the company before the update in pancreatic cancer, where nothing seems to work.

ohad

'When There's Blood in the Streets', Buy Biotech Stocks

Thanks, KevinMBK.
I don't follow CYPB closely, but I think there is a lot of skepticism towards upcoming phase III results for milnacipran . Their cash position is enviable, no doubt.

Ohad

'When There's Blood in the Streets', Buy Biotech Stocks

Thanks, jturano7423.

I don't think it has a lot to do with guts, but basic common sense ( which seems to be a scarce commodity these days). History shows that people tend to exaggerate to both ways, and what we're witnessing, including today's selloff is merely a result of irrational behavior. Yes, things don't look good at the moment but in my opinion, now is the time to build positions selectively in segments and companies who can weather the storm. I think good biotech companies represent such a tremendous opportunity because their products and technology will always be in demand. Even companies who won't have a commercially available drug in the near future will be able to license drugs and technology to the pharmaceutical giants, who have deep pockets and are starved for new drugs. Remember: There is always a good market for good drugs.
I personally feel much more comfortable buying today, when all the fund managers and investors are dumping everything they have. They were the ones that accumulated all these stocks in the past year or two.

Ohad

'When There's Blood in the Streets', Buy Biotech Stocks

Sorry petpesie, I am not familiar with BioMS. I am sure there are plenty of biotech companies that are suffering as a result of this panic. From what you describe, it is in good position because it has Lilly paying for clinical development, and it doesn't seem that it would stop doing just because there's a recession.